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Abstract 
Rationale: Brain reward pathways implicated in addiction appear to be less reactive in 
regular drug-users; behavioural manifestations may include decreased sensitivity to 
natural reinforcers.   
Objectives: This study aimed to replicate earlier findings of abstinence-associated 
incentive motivation deficits in smokers and to determine whether these can be 
reversed with nicotine in the form of lozenge.  
Methods:  145 smokers were each tested twice, once after receiving nicotine, and 
once after receiving placebo lozenge in counterbalanced order.  Participants 
completed various tests of incentive motivational functioning: a measure of subjective 
enjoyment, the Snaith-Hamilton Pleasure Scale (SHAPS); a simple card sorting task, 
the Card Arranging Reward Responsivity Objective Test (CARROT) with and 
without financial incentive; the modified emotional Stroop test; a cue-reactivity task; 
and a novel reaction time task to explore effects of signals of reward, the Incentive 
Motivational Enhancement of Response Speed (IMERS) Task. 
Results: Compared with performance during abstinence (placebo condition), nicotine 
was associated with: higher self-reported pleasure expectations on the SHAPS; 
enhanced responsiveness to financial reward on the CARROT in smokers who 
smoked 15 or more cigarettes a day; and greater interference from appetitive words on 
the Stroop task. 
Conclusions:  These results are generally consistent with contemporary 
neurobiological theories of addiction and suggest that short-term smoking abstinence 
is associated with impaired reward motivation which can be reversed with nicotine.  
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Introduction  
Contemporary neurobiological models of addiction strongly implicate brain ‘reward’ 
pathways comprising dopaminergic projections from ventral tegmental area (VTA) to 
nucleus accumbens (N.Acc), amygdala, anterior cingulate gyrus (CG) and prefrontal 
cortex (PFC; e.g. Goldstein and Volkow 2002; Robinson and Berridge 1993, 2000).  
These tracts are collectively referred to as the mesocorticolimbic system, and 
dopamine (DA) release in the N.Acc in particular has been associated with appetitive 
responding for a range of ‘natural’ rewards including food and sex and as well as for 
drugs of abuse (including cocaine, amphetamine, alcohol, cannabis and nicotine; 
Bozarth 1991; Corrigal 1992).  It has been argued that drugs of abuse ‘hijack’ the DA 
system (Lubman et al. 2004) since they are capable of inducing significantly greater 
magnitude and longer duration increases in DA levels than are natural reinforcers.   
Rather than being exclusive to reward however, DA release has been implicated in 
responses to stimuli with other types of motivational salience including aversion and 
novelty (Gray 1997; Salamone 1994; Volkow et al. 2004a).   
 
Robinson and Berridge (1993, 2000) propose that chronic drug use sensitises 
(increases the reactivity of) the brain reward system involved in the attribution of 
incentive properties to rewarding stimuli and the instigation of approach behaviour. 
They argue that repeated drug use leads to exaggerated orienting of attention towards 
drug-related cues so that they become especially salient, attractive and ‘wanted’.  The 
‘wanting’ triggered by exposure to drug-related cues during the early phases of drug 
use evolves into the phenomenological experience of craving; ensuing behavioural 
consequences are likely to be compulsive drug seeking and consumption.   
 
Although addicts may continue to experience the acute DA-enhancing effects of 
drugs, there is increasing evidence that tonic levels of dopamine are reduced in 
chronic users (see review by Volkow et al. 2004b).  PET and SPECT studies have 
revealed lower DA D2 receptor availability in the striatum of abstinent drug-addicted 
individuals compared with controls (Volkow and Li 2004), paralleled by a decrease in 
striatal DA release (Volkow et al. 1997).  Reduced DA D1 receptor binding in the 
N.Acc. has also been reported in the brains of human smokers compared with non-
smokers (Dagher et al. 2001).  Whether these abnormalities are a result of extended 
drug exposure, or reflect characteristics that pre-existed, and possibly predisposed to, 
drug taking is still unclear.  Either way, various authors, including Al-Adawi and 
Powell (1997), Caggiula et al. (2001) and Volkow et al. (2004b), suggest that this 
dampened DA activity is likely to result in decreased reactivity to natural (and 
secondary) reinforcers.   
 
Imaging studies support the notion of disrupted sensitivity to non-drug rewards in 
addicts.  For example, using fMRI, Martin Sölch et al. (2001a) found more extensive 
activation of dopaminergic brain circuitry in non-smokers than in smokers during a 
task involving monetary reward.  In a second study investigating the effects of 
different types of reward cue, opiate addicts showed decreased limbic activation 
during presentation of monetary rewards compared with controls, but the opposite 
pattern of activation in response to drug-associated cues (Martin-Sölch et al. 2001b).  
Others have also shown that exposure to drug-related cues in addicts, including 
smokers, results in both craving and activation of brain regions innervated by the 
mesocorticolimbic reward circuitry (Brody et al. 2002; Childress et al. 1999; David et 
al. 2005; Volkow et al. 1999).  Nevertheless, we have found that cue-elicited craving 
is not increased, and may even be decreased, in abstinent smokers (Powell et al. 
2002a).  Few neuroimaging studies have specifically compared abstinence and 
satiated smokers though one recent report found no effects of abstinence/satiety on 
patterns of brain activation in response to smoking cues (McClernon et al. 2005). 
 
Thus, regular smokers may simultaneously possess a hypofunctioning tonic DA 
system but experience DA-enhancing effects of cigarette smoking.  Their 
hypofunctioning DA system would thus be disguised as long as they are smoking but 
‘unmasked’ during periods of acute abstinence - for example, at the start of a quit 
attempt, manifesting in blunted motivational and emotional responses to natural 
reinforcers.  The pharmacological ‘boost’ achieved via smoking a cigarette, or taking 
nicotine replacement therapy, would reinstate ‘normal’ behavioural and emotional 
reactivity.  
 
Consistent with this hypothesis, we have consistently found that abstinent smokers 
show reduced responsiveness to a financial incentive on a simple psychomotor card 
sorting task (the Card Arranging Reward Responsivity Objective Test [CARROT]) 
compared to both non-smokers and recent smokers (Al-Adawi and Powell 1997; 
Powell et al. 2002a; Powell et al. 2004).  Powell et al. (2002a; 2004) additionally 
found that abstinent smokers report deriving less enjoyment from a range of ordinarily 
pleasurable events and activities as assessed by the Snaith-Hamilton Pleasure Scale, a 
self-report measure of affective responses to rewards in daily life (SHAPS; Snaith et 
al. 1995).  Using a more ecologically valid paradigm, we have recently demonstrated 
that abstinent smokers experience less emotional ‘uplift’ after viewing positively-
valenced (happy) film clips than do smokers who have recently smoked (Dawkins et 
al. in press).  Their responses to neutral and sad clips, by contrast, were not affected.  
 
The ability of nicotine to amplify the incentive value of other positive reinforcers has 
also been noted in the preclinical literature: for instance, rats will make more 
responses for a conditioned positive reinforcer in an environment previously paired 
with nicotine than in an environment previously paired with saline (Olausson et al. 
2004).  Thus, naturally rewarding stimuli that are motivationally salient for the 
general population may elicit weaker positive motivational and affective responses in 
drug users during periods of abstinence.  This may in turn be associated with a 
subjective state of dysphoria or anhedonia which can effectively be alleviated by 
renewed drug use.   
 
If, as argued by Salamone (1994) and Robinson and Berridge (2000), DA release in 
response to motivationally salient cues is associated with increased attention towards 
them, it follows that abstinence should be associated with decreased, and smoking 
with increased, allocation of attention towards stimuli of motivational salience.  It is 
relevant to note here that whereas Robinson and Berridge’s (1993; 2000) incentive 
sensitisation model restricts itself to the appetitive domain others highlight the critical 
involvement of DA in responses to stimuli with both appetitive and aversive 
motivational salience (Gray et al. 1997; Salamone 1994).  Using an ‘emotional’ 
variant of the Stroop task in which participants had to name the ink colour of 
appetitive, aversive and neutral words, we previously found that non-smokers, and 
smokers who had just had a cigarette, were slower than abstinent smokers in colour-
naming both appetitive and aversive words compared with neutral words (Powell et 
al. 2002b). This indicates reduced attentional ‘capture’ by motivational words in the 
latter group regardless of their valence.   
 The present study aimed to replicate and extend the findings of Powell et al. (2002a, 
2002b).  Neither of these previous studies used a blinded design and both used 
smokers who had either abstained or recently smoked cigarettes; thus the observed 
performance enhancements may have reflected demand characteristics and could not 
definitively be attributed to nicotine since this is one of many active ingredients in 
cigarettes.  The present study isolated the influence of nicotine, administered in 
lozenge form, using a double-blind, placebo-controlled design. 
The following specific hypotheses were tested: 
1. Motivational and affective responses to non-drug incentives will be dampened 
during abstinence and normalised by acute nicotine consumption.  If activity in the 
dopaminergic reward pathways is indeed compromised in chronic smokers then 
abstinence should be associated with reduced attentional, behavioural and subjective 
responsiveness to everyday incentives.  Conversely, by triggering DA release in the 
N.Acc shell, (Gamberino and Gold 1999), nicotine ingestion should increase the 
reactivity of the reward system, thus enhancing these behavioural and subjective 
responses.  These processes are measured here using three experimental tasks and one 
self-report measure.  
 
2. Increases in self reported craving in response to the sight and smell of a 
cigarette will be greater after participants have received nicotine relative to placebo.  
We likewise hypothesise that cue-elicited craving will be reduced during abstinence 
and enhanced after receiving nicotine.  This effect was reported by Payne et al. (1996) 
and observed in our earlier study (Powell et al. 2002a) consistent with priming 
studies, which have demonstrated inflated desire for, or use of, a drug following a 
small dose of the same or another drug (e.g. Spiga et al. 1998).  However, others have 
argued that abstinence should increase cue-reactivity by inducing a deprivation state 
and thus enhancing the salience of drug-related cues (e.g. Baker et al. 1987) although 
we have been unable to find any empirical support for this in the literature. 
 
Materials and methods 
Design 
In this repeated measures design, 145 smokers were tested on two occasions a week 
apart, following overnight (12 hours) abstinence from smoking on both occasions.  On 
one occasion they received 4mg of nicotine (the dose given clinically to smokers who 
smoke within 30 minutes of waking, as did the majority of the present sample) via 
NiQuitin lozenge and on the other, a placebo lozenge.  Nicotine in lozenge form was 
used since the manufacturer (Glaxo Smith Kline) was able to provide unmarked 
nicotine and placebo lozenges, comparable in appearance and taste.  Order of testing 
was counterbalanced and participants were required to suck (and not chew) the 
lozenge for 30 minutes before commencement of testing to allow time for nicotine to 
reach the bloodstream.  One hour into the testing session, a second ‘top-up’ lozenge, 
identical to the first, was given with the aim of achieving fairly stable blood nicotine 
levels across the 2-hour testing session.  Both participant and experimenter were blind 
to experimental condition.  This study was part of a larger overall study which aimed 
to explore effects of nicotine and abstinence on motivational, cognitive and 
personality variables.  Here we report just those relating to incentive motivational 
functioning (see accompanying paper for measures pertaining to inhibitory control 
and executive functioning).  Table 1 provides a schematic overview of design/order of 
task administration. 
Table 1 
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Participants 
Participants were recruited through adverts in local newspapers, radio stations, 
colleges, libraries and pharmacies in the South East London area and were paid for 
their participation.  All were aged between 18 and 65, had smoked more than 10 
cigarettes a day for at least one year, and reported smoking within the first hour of 
waking up in the morning.  Exclusion criteria included pregnancy, serious heart 
disease or recent stroke, a current psychiatric or neurological diagnosis, regular use of 
prescription (or class A recreational) drugs, and salivary cotinine levels of less than 
20ng/ml (which is inconsistent with active smoking; Jarvis et al. 1987). 
 
Expired CO samples were taken prior to each experimental testing session to verify 
compliance with the request to remain abstinent.  Participants with a reading in excess 
of 10ppm on either occasion were excluded from the present study since they could 
not be considered nicotine-free prior to the experimental manipulation.  
 
Written informed consent was obtained before participation in the study which was 
approved by Goldsmiths College Ethics Committee.   
 
Assessment Measures 
Baseline Assessments   
Salivary Cotinine.  All participants provided a saliva sample a few days prior to 
commencement of the experimental testing sessions.  Cotinine, a metabolite of 
nicotine, with a half-life of 48 hours, is the most sensitive marker of recent nicotine 
intake and saliva levels were measured using gas chromatography.  Regular smokers 
typically show salivary cotinine levels in the region of 330ng/ml (compared to < 
20ng/ml in non-smokers; Jarvis et al. 1987).   
 
Expired carbon monoxide.  Breath CO levels were taken at the beginning of each 
testing session.  The half life of CO is approximately 4 hours, thus scores of lower 
than 11ppm are expected in smokers who have complied with the instruction to 
abstain for 12 hours (Hughes et al. 1978). 
 
The Fagerström Test of Nicotine Dependence (FTND; Heatherton et al. 1991) 
This 6-item self-report scale assesses nicotine dependence.  Scores range from 0 (low 
dependence) to 10 (high dependence).   
 
Dependence scale from the Smoking Motivation Questionnaire (SMQ; West and 
Russell 1985).   Participants rate the extent to which each of 9 statements apply to 
them using a 4-point scale.  Total score ranges between 0 (low dependence) and 27 
(high dependence). 
 
Demographic information (including age, gender, ethnicity, socioeconomic status, 
educational level) and further data on smoking habits (number of cigarettes smoked a 
day, number of years of smoking and number of quit attempts) were also collected.  
 Measures of Incentive Salience/Reward Motivation 
The first four measures described here were as administered in our previous studies 
(Powell et al. 2002a; 2002b; 2004) 
 
Anhedonia: The Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995). This 
14-item self-report scale is designed to measure hedonic tone in both healthy and 
clinical populations. Subjects indicate the extent to which they agree or disagree with 
a series of statements (for example, ‘I would enjoy my favourite television or radio 
programme’) relating to their expected enjoyment of a range of normally pleasurable 
events or activities ‘at this moment’.  Items were scored 0 (strongly agree) to 3 
(strongly disagree) yielding a score range from 0 to 42 with a higher score indicating 
greater anhedonia.  
 
Card Arranging Reward Responsivity Objective Test (CARROT; Al-Adawi and 
Powell 1997).  This simple card sorting task, described in detail elsewhere (see Al-
Adawi and Powell 1997), measures the extent to which participants’ psychomotor 
performance is enhanced by financial incentive.  Participants are required to sort cards 
according to a simple rule, firstly during a baseline familiarisation trial (B) and then 
under conditions of reward (R) and no explicit reward (NR), presented over three 
experimental trials in the order NR1, R, NR2.  The average card sorting rate (cards 
per second) in the two non-rewarded trials is computed and the rate of increase in card 
sorting under R versus NR is taken to index ‘reward responsivity’.  
 
Modified Stroop test of attentional bias (Powell et al. 2002b).  This measures the 
extent to which attention is ‘captured’ by various classes of motivationally salient 
stimuli.  Participants are required to colour-name the ink (red, green, yellow or blue) 
in which each of 88 words (11 repetitions of 8 different words from a single semantic 
category) is printed.  We used a card version of this task (consistent with our previous 
study), with the 88 words appearing in 4 columns which participants are required to 
colour name sequentially (vertically downwards) and correct themselves if they make 
an error.  Four classes of semantic stimuli (neutral, appetitive, aversive and smoking-
related [e.g. cigarette, smoke, lighter]), matched for word frequency and length, are 
presented on separate cards in counterbalanced order.  In our previous study we 
compared both appetitive and aversive stimuli with neutral stimuli; here we 
additionally included smoking-related words.  These may have either appetitive or 
aversive connotations to individual smokers, depending on how they currently feel 
about smoking and possible cessation, and are more likely to engage cognitive 
processes than are the other categories of words. In the results section we explore how 
each separate semantic category of word is affected by nicotine vs. abstinence.  
Number of errors and total naming time (no. of seconds to complete colour-naming of 
all 88 words) are recorded for each of the four word types.   
 
Cue Reactivity 
Smokers rated their craving for a cigarette, and also their withdrawal symptoms: (i) at 
baseline, before cue-exposure; (ii) following 2 minutes exposure to a neutral cue 
(taking Scotch tape out of a box and sniffing it); and (iii) after 2 minutes exposure to a 
cigarette of their preferred brand (taking the cigarette out of its box and sniffing it).  
 
Craving was assessed via ratings of the single item, ‘How strong is your desire to 
smoke right now’ on a 7-point Likert scale ranging from 1 (not at all strong) to 7 
(extremely strong).  
 
The severity of seven symptoms commonly associated with nicotine withdrawal 
(depression, irritability, anxiety, drowsiness, restlessness, hunger, poor concentration) 
was assessed using the Mood and Physical Symptoms (MPS) Scale (Hughes and 
Hatsukami 1986).  Each item was rated on a 5-point scale (0-4).  The total score could 
range from 0 to 28 with a higher score reflecting greater severity of withdrawal 
symptoms/negative mood.  
 
Incentive Motivational Enhancement of Response Speed (IMERS) Task (Pickering 
2004).  In addition to the above well-validated measures, we also included a novel 
conditioning task (IMERS) recently developed by Pickering (but as yet, not tested on 
smokers) to explore reward motivation in a different way.  This task measures the 
extent to which reaction time in a simple choice reaction time paradigm is affected by 
a) novel neutral stimuli and b) novel conditioned rewarded stimuli.  In an initial 5 
minute conditioning phase, participants acquire a non-instrumental association 
between the presentation of a specific geometric shape (star, square, triangle or 
diamond, counterbalanced across participants and condition) and winning money.  To 
achieve this, participants sit in front of a computer screen and hold a rubber bulb 
which they are required to alternatively squeeze and release on command.  They are 
told that they can win up to £3.00 but that this has nothing to do with the way they 
squeeze the bulb, the decision instead being randomly made by the computer.  After 
each ‘squeeze and release’ of the bulb, the computer screen displays either the 
participant’s ‘lucky’ symbol (a white star, square, triangle or diamond, selected quasi-
randomly for each participant), in which case the experimenter places a 50 pence 
piece on the table beside the participant, or the ‘unlucky’ symbol (a pentagon) in 
which case they receive nothing.  A ‘prize bar’ displayed on the right hand side of the 
screen logs cumulative winnings.   
 
Following the conditioning phase, the participant is given his or her winnings (always 
between £2 and £3) and then completes a 2 minute practice choice reaction time task 
followed by a 5 minute experimental task.  The target stimuli for the choice reaction 
time task consist of the letters H and L presented one at a time in the centre of the 
screen.  Participants are instructed to hit the H key in response to H using the 
forefinger of their left hand, and the L key in response to L using the forefinger of 
their right hand as quickly and as accurately as possible.  Just prior to each target 
stimulus presentation, a rapid (1 second) sequence of distractor stimuli is presented 
consisting of 4 circles of different colours, each occurring for 250 msec.  In standard 
trials these follow a constant pattern of four changes in colour and position, peripheral 
to the target stimulus (occurring at 9, 12, 3 and 6 o’clock in blue, green, red and white 
respectively).  The practice phase consists of 40 standard trials and runs into the 
experimental phase without a break.  There are 130 trials in the experimental phase; 
on six of these, a randomly selected ‘novel’ associative mismatch (AM) occurs.  Here, 
an unexpected peripheral distractor appears on the fourth step (at 6 o’clock), 
consisting of a white hash sign or four small circles (AM trial).  On a further six trials, 
the individual’s conditioned rewarded stimulus (white star, square, triangle or 
diamond) occurs in the fourth position (‘signal of reward’ [SR] trial).  AM and SR 
symbols are counterbalanced across participants and testing session.  Every AM and 
SR trial is preceded by a ‘standard’ trial which acts as a direct reference for AM and 
SR slowing or speeding effects (see Figure 1). 
 
 
Figure 1 here
  
 
Reaction time (RT) differences (AM trial minus its paired standard trial or SR trial 
minus its paired standard trial) are computed based only on those trials which receive 
a correct response and when the control trial preceding it also receives a correct 
response.  These scores provide indices of the change in speed attributable to AM or 
SR (where a positive value indicates a slowing and a negative value a speeding of 
response).  Participants whose RT is based on 2 or fewer trials are excluded.   In order 
to specifically measure the speeding effect of signals of reward on RT, mean RT for 
AM trials was subtracted from mean RT for SR trials.  Negative differences represent 
facilitation by reward and positive differences represent slowing by reward.   
 
In previous work with a healthy student sample (Pickering et al. 2001) the unexpected 
AM distractor stimulus produced a highly significant inhibitory slowing of RT 
compared with standard trials.  On SR trials this effect was not observed.  Pickering 
(2004) suggested that the mismatch effect was still present on SR trials but was offset 
by a motivating and speeding effect triggered by the signal of reward.  The degree to 
which the speeding effect associated with SR cancelled out the slowing effect 
associated with AM (i.e. AM minus SR) has been shown to be predicted by 
extraversion (r = 0.32; see Pickering 2004), a trait putatively associated with 
functioning of the mesocorticolimbic DA system (Depue and Collins 1999).   
 
In the present context, we predicted that, due to their dampened DA system, abstinent 
smokers would be less reactive to signals of reward manifesting in larger (less 
negative) AM minus SR difference scores compared with their responses after 
nicotine administration.  
 
Statistical Analyses 
Data were analysed using repeated measures analysis of variance (ANOVA) with 
lozenge type (LOZTYPE: nicotine vs. placebo) as the within-subjects factor and order 
of lozenge administration as a between subjects factor (LOZORDER: nicotine first vs. 
placebo first).  Lozenge order is only discussed where a significant main effect or 
interaction involving LOZORDER is found.  These analyses were also repeated a) 
with just the heavier smokers (≥ 15 cigarettes a day) for direct comparability with the 
participants in our earlier study (Powell et al. 2002a) and b) with GENDER as a 
between subject factor, however, in the case of b), no significant effects were found 
thus gender is not discussed further.  
 
Between-groups analyses were also conducted for Time 1 data only, given that the 
blinding procedure was less effective at Time 2; however the patterns of results did 
not differ from those of the repeated measures ANOVAs and so are not discussed 
further.     
 
Results 
Descriptive statistics for the two groups receiving nicotine and placebo lozenges in 
different orders are displayed in Table 2.  The two groups did not differ from each 
other in sex ratio (χ2 = 0.31, df = 1, ns), age (t143 < 1, ns), years in tertiary education 
(t142 < 1.5, ns), or any of the smoking-related variables (t143 < 1.6, ns in each case).    
 
Both craving and withdrawal symptoms (MPS) were higher in the placebo than 
nicotine condition (craving: F1,143 = 21.95, p < 0.0001; MPS: F1,143 = 6.65, p = 0.01) 
and did not differ significantly between the two groups (craving: F1,143 = 2.79, p = 
0.10; MPS: F1,143 = 1.57, ns; See Table 2). 
 
 
Table 2 
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Participants were asked which lozenge (nicotine or placebo) they thought they had 
received at each testing session.  55% of participants guessed correctly at time 1, a 
figure at chance level (χ2 = 1.67, ns), whilst 69% guessed correctly at time 2 (χ2 = 
21.57, p < 0.001).  These figures suggest that the blinding procedure worked very 
well for participants at time 1 but less well at time 2.  
 
SHAPS anhedonia 
Four participants failed to complete this questionnaire.  For the remaining 141 
participants, the main effect of LOZTYPE was significant (F1,139 = 6.31, p < 0.02) 
reflecting greater anhedonia in the placebo (mean = 9.63, SD = 5.90) than in the 
nicotine condition (mean = 8.67, SD = 5.82).  This effect remained significant when 
change in withdrawal symptoms (placebo minus nicotine) was covaried out (F1,138 = 
4.40, p < 0.05). 
 
CARROT reward responsivity 
REWARD (reward vs. non-reward trials) was an additional within-subjects factor in 
the ANOVA. 
 
Rate of card sorting was significantly faster in the rewarded trial (REWARD: F1,143 = 
11.24, p = 0.001) but did not differ according to lozenge type (LOZTYPE: F1,143 < 1, 
ns).  There was a trend towards the predicted REWARD X LOZTYPE interaction 
(F1,143 = 2.16, p = 0.14) reflecting almost identical rates of card sorting under nicotine 
and placebo conditions in the non-rewarded trials, but faster rates in the rewarded trial 
in the nicotine condition (see Figure 2).  This interaction however, was significant in 
the heavier smokers (≥ 15 cigarettes a day, N = 113; F1,111 = 4.06, p < 0.05), consistent 
with the findings from our previous study (Powell et al. 2002a). 
 
 
 
Figure 2 here 
 
Modified Stroop 
WORDTYPE (neutral, pleasure, aversive, smoking) was included in the ANOVA as 
an additional within-subjects variable.  To test the specific theoretical questions of 
interest here relating to the involvement of DA in appetitive and aversive motivation 
separately, a priori contrasts were specified within ANOVA to compare words with 
appetitive, aversive and smoking connotations against neutral words (one-tailed).  
Thus it is the a priori contrasts rather than omnibus effects that are of specific interest 
here. 
 
Errors 
Individual subjects tended to make few errors on this task (overall mean: 1.07 [1.23]; 
range 0-7; see Figure 3).  There were no main effects of either WORDTYPE (F3,140 < 
1, ns) or LOZTYPE (F1,140 < 1, ns), and the omnibus LOZTYPE X WORDTYPE 
interaction also fell short of significance (F3,426 = 1.26, ns).  However the a priori 
contrasts revealed a significant LOZTYPE X WORDTYPE interaction specifically 
for pleasure vs. neutral words as predicted (t142 = 1.71, p < 0.05 for a 1-tailed test) but 
not for either aversive or smoking-related vs. neutral words (t142 < 1, ns in both cases).  
Since error data were distributed in a non-normal fashion, a non-parametric Wilcoxon 
signed ranks test was additionally conducted on the change scores (pleasure-word 
errors minus neutral-word errors) for the nicotine and placebo conditions.  This 
revealed a significant difference for pleasure vs. neutral words (Z = -1.67, p < 0.05 for 
a 1-tailed test). 
 
Figure 3 here  
 
 
Naming Speed 
For overall colour-naming time, there was a main effect of WORDTYPE (F3,140 = 
22.23, p < 0.0001) reflecting faster colour-naming of neutral words, no main effect of 
LOZTYPE (F1,142 = 1.39, ns) and no LOZTYPE X WORDTYPE interaction (F3,426 < 
1, ns).  The a priori contrasts revealed no significant LOZTYPE X WORDTYPE 
interaction for any of the three salient word types (pleasure, aversive, smoking) 
relative to neutral words (F1,142 < 1, ns in each case). 
 
Cue-Elicited Craving and Withdrawal 
ANOVA included the additional within-subjects factor of EXPOSURE (neutral cue 
vs. cigarette cue). 
 
As expected, both craving and withdrawal symptoms (MPS scores) were significantly 
higher in the placebo than nicotine condition (main effect of LOZTYPE: F1,142 = 
28.62 and 8.37, p < 0.005, for craving and withdrawal symptoms respectively).  
Craving was also higher in response to the sight and smell of a cigarette than a neutral 
cue (main effect of EXPOSURE: F1,142 = 90.56,  p < 0.0001) although withdrawal 
symptoms were not (F1,142 < 1, ns).  There were no LOZTYPE X EXPOSURE 
interactions (F1,138 < 1, ns in both cases; see Table 3). 
 
Table 3 
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IMERS Task 
Fourteen participants did not complete this task as a result of technical problems with 
the computerised task; a further 11 participants were excluded from the AM analysis, 
and 9 from the SR analysis, because there were 2 or fewer valid trials (i.e. where both 
the experimental and preceding control trial are responded to correctly).  These 
analyses were therefore based on 120 participants for AM trials and 122 for SR trials.  
Mean RTs for AM and SR trials, their paired standard control trials and the AM-SR 
differences are presented in Table 4. 
 
For the ‘AM minus paired control trials’ difference score there was a significant effect 
of LOZTYPE (F1,118 = 6.11, p < 0.05), reflecting a smaller RT difference with 
nicotine than placebo.  However there was no significant effect of LOZTYPE on the 
‘SR minus paired control trials’ difference score (F1,120 = 1.16, ns), nor on the critical 
AM-SR difference score (F1,116 < 1, ns). 
 
 
 
Table 4 
here 
Discussion 
Using a double-blind, placebo-controlled design of pure nicotine administration in a 
large sample of smokers, this study aimed to subject to more rigorous test our 
previous findings that during abstinence, smokers show reduced behavioural 
responsiveness to, and dampened subjective enjoyment of, incentives; and that these 
effects are reversible by smoking.  These previous studies could not unambiguously 
attribute the observed effects to nicotine, firstly because the non-blinded designs left 
open the possibility of expectancy effects, and secondly because the smoking 
manipulation entails exposure to multiple psychoactive substances in tobacco.  
Generally speaking, the present results did corroborate these findings and confirmed 
that pure nicotine can reverse abstinence-related deficits which we have previously 
demonstrated to improve following cigarette smoking (Al-Adawi and Powell 1997; 
Powell et al. 2002a, 2002b).   
 
On the SHAPS, abstinent smokers reported that they would expect to derive less 
enjoyment from a range of ordinary events and activities compared with their reports 
after receiving nicotine.  Although one might expect smoking abstinence to be 
associated with a general malaise and anhedonia when smokers are aware of their 
deficit state, it was striking here that the effect was apparent despite the fact that 
participants were unable to judge whether they had received nicotine or not.  
Moreover, this effect remained significant when we controlled for subjectively rated 
withdrawal symptoms.  Thus, the presence of nicotine delivered via lozenge does 
have a positive impact on hedonic tone, an effect that appears to be distinct from its 
effects upon the general symptoms of nicotine withdrawal.    
 
Although the effect of nicotine on the CARROT reward responsivity measure here 
fell short of statistical significance within the whole sample, a significant effect was 
found in the heavier smokers (> 14 a day) who were directly comparable to those 
tested in our earlier study (Powell et al. 2002a).  Specifically, during acute abstinence 
smokers showed virtually no reward responsivity (i.e. increase in speed of card 
sorting on the rewarded relative to the non-rewarded trials) but a significant effect 
after receiving nicotine.  This confirms our predictions, at least in heavier smokers, 
that acute abstinence would be associated with weakened incentive motivation 
(putatively reflecting low levels of mesocortiocolimbic DA activity), and that this 
would be reversed by administration of pure nicotine.  It is plausible, both 
theoretically and pharmacologically, that ingestion of nicotine by lozenge enhances 
responsiveness to incentives via its impact on mesocorticolimbic DA.  Although we 
cannot unambiguously draw this conclusion, or indeed be certain of the impact of 
orally administered nicotine on the dopamine system, we note that systemic 
application of nicotine in animals is known to trigger DA release in the 
mesocorticolimbic system (Rahman et al., 2003). 
 
There was also partial support for the hypothesis that nicotine would increase 
attentional bias towards stimuli with appetitive salience.  Specifically, on the 
emotional Stroop task, participants made a relatively greater number of errors in 
colour-naming ‘pleasure-related’ words (e.g. love, adventure, euphoria) after 
receiving the nicotine lozenge than the placebo lozenge.  This is consistent with 
Robinson and Berridge’s conceptualisation of addictive drugs priming the reward 
pathways such that these appetitively salient words ‘grab the attention’ and 
accordingly impede the individual’s ability to focus on other properties of the stimuli.  
Interestingly, however, the pattern of findings did not exactly replicate those found in 
our previous studies examining the effects of cigarette smoking on this task (Powell et 
al. 2002b).  Thus the effect of nicotine did not manifest here in terms of overall speed 
of colour-naming of different word types, nor was the previously observed effect of 
smoking on increasing attentional bias to aversive/threat-related words (e.g. lonely, 
ashamed, emergency) replicated.  These discrepancies might be attributable to 
methodological differences between the studies such as the different routes, levels, or 
speed of nicotine administration or to the other psychoactive components present in 
tobacco but not in lozenge.  Further comparative studies would be needed to 
investigate these potential explanations.   
 
There was no effect of nicotine on either error rate or response times to smoking-
related words.  Elsewhere, research using this paradigm has produced mixed results; 
some studies have found smokers to show attentional bias towards smoking-related 
cues during abstinence (e.g. Gross et al. 1993; Waters et al. 2003) whilst others have 
reported such biases after recent smoking (Johnsen et al. 1997); others still have 
reported no effect of abstinence versus recent smoking (Munafo et al. 2003; Rusted et 
al. 2000).  In fact it is difficult to test the neurobiological model of addiction in 
relation to bias towards smoking-related words since both neurochemical and explicit 
cognitive processes, which affect attention towards such cues, are likely to be 
simultaneously involved, not necessarily working in the same direction.  Thus, during 
acute abstinence a smoker is likely to be consciously preoccupied with thoughts of 
smoking.  This will therefore lead to ‘semantic priming’, i.e., preferential processing 
of stimuli (words, pictures and so on) semantically related to smoking.  This effect 
would tend to oppose any abstinence-related reduction in neurobiological ‘appetitive 
priming’ (i.e. impaired sensitivity to cues with any type of appetitive significance).  
Conversely, in the satiated state, smokers are less likely to be thinking about their 
desire to smoke and so semantic priming will be less, but for the reasons previously 
discussed, neurobiological ‘appetitive priming’ will be elevated.  Since the relative 
impact of these two sources of salience attribution/attentional bias are likely to depend 
on numerous factors (for example, length of abstinence, dose of nicotine, level of 
dependence, expectation about smoking after the experiment etc.), almost any pattern 
of results can be explained by recourse to this dual-route model.  Accordingly, we 
recommend the use of non-drug-related appetitive cues to provide a ‘clean’ test of the 
incentive sensitisation model of addiction.  Nevertheless, inclusion of drug-related 
cues is clearly of considerable clinical relevance to understanding multiply-
determined ‘real-world’ outcomes.       
 
Relatedly, we have argued that ‘appetitive priming’ via nicotine administration would 
increase cue reactivity in the form of craving elicited by cigarette-related cues.  Some 
data consistent with this hypothesis have been reported (Powell et al. 2002a; Payne et 
al. 1996).  By contrast, others (e.g. Baker et al. 1987) have argued that the incentive 
salience of such cues would be increased during abstinence.  Interestingly however, 
we are unaware of any studies which have demonstrated elevated cue reactivity 
during acute abstinence by comparison with a satiated condition. Again, we note the 
possibility that two independent (and potentially opposing) biological and semantic 
priming mechanisms are likely to be involved.   
 
Here, in one of the largest and best-controlled studies to date of cue-reactivity as a 
function of nicotine status, we found no difference between abstinent and satiated 
conditions in the increase in craving elicited by a smoking cue relative to that elicited 
by a neutral cue.  This finding does not confirm the biologically based prediction of 
elevated cue reactivity after nicotine intake.  It does suggest that if there is an effect of 
abstinence in promoting the incentive value of smoking cues, then it is offset by some 
other process.  We would argue that this other process might be the biological 
incentive sensitisation effect.  The relative influence of these two putative routes is 
obviously difficult to explore empirically, although one possibility might be to 
include, prior to the Stroop task, some measure of current cognitive content (e.g. by 
asking participants to rate the frequency/extent to which they are thinking about 
smoking).  This could then be used as a predictor in the statistical analysis of colour-
naming errors/speed.   
 
It is also possible that the single-item index of craving used here lacked sensitivity to 
‘real’ underlying effects of nicotine. In our previous study in which we did find an 
effect we used a broader multi-item measure (QSU); future research might usefully 
compare different techniques of assessment. 
 
In clinical terms, the fact that this study reveals no impact of nicotine lozenge in 
reducing cue reactivity, suggests that nicotine replacement therapy (NRT) may not 
protect against surges of craving that smokers attempting to quit might experience in 
smoking-related situations.  Indeed, although NRT is effective in helping smokers to 
quit, nevertheless, 78-90% still relapse (Hyland et al. 2005; Swartz et al. 2005).  This 
raises the possibility that concurrent treatment with other medications which do 
attenuate cue reactivity should be considered.  In this regard, it is interesting that, in a 
recent PET study with smokers, bupropion treatment attenuated both cue-induced 
anterior cingulate cortex activation and craving (Brody et al. 2004).   
 
The IMERS task was the only measure not previously used in our research with 
smokers.  As previously found by Pickering (2004), associative mismatch (AM) trials 
produced a slowing of response whilst signal of reward (SR) trials went some way to 
offsetting this.  Interestingly, the AM effect was smaller in the nicotine than placebo 
condition suggesting that nicotine had a speeding effect on AM trials.  This is likely to 
be due to the stimulant properties of nicotine.  However, contrary to our prediction, 
there was no difference between nicotine and placebo conditions in the speeding 
effect of signals of reward.  This result appears to conflict with the observed effect of 
nicotine on CARROT reward responsivity.  Clearly there are a number of potentially 
relevant procedural differences between the tasks which could account for the 
apparent discrepancy.  For instance, the CARROT involves an instrumental response-
outcome link; increasing speed of card sorting on the reward trial produces more 
financial gain.  By contrast, there is no such response-outcome association in the 
IMERS task; the speed of response has no implication for the participant’s personal 
gain.  Aspects of reward pathway function putatively affected by drug priming 
include a) attentional processing of reward cues with concomitant motivational effects 
and b) using incentive information to strategically enhance instrumental behaviours 
orientated to obtaining a reward.  Whereas the CARROT involves both these 
putatively drug-dependent processes, the IMERS involves only the former.  If only 
the latter process is important however, then only the CARROT should be affected by 
drug priming.  
 
The present effect sizes were somewhat smaller than in our previous studies which 
compared acute abstinence with smoking.  This might reflect the influence of 
expectancy effects/demand characteristics previously, the different routes of nicotine 
administration, or a combination of both.  Nicotine delivered via cigarette smoking 
achieves high levels in the blood and rapid surges of nicotine (as a bolus) to the brain 
(Russell 1976); administration via lozenge or gum, by contrast, is much slower, 
reaches only one-third of these levels and does not produce the bolus of nicotine to 
the brain achieved via smoking (Keenan et al. 1995).  Thus smoking may be a more 
potent method of reversing reward motivational impairments through its ability to 
deliver high concentrations of nicotine and to do it quickly.  It would be interesting in 
future studies to explore the dose-response relationship between nicotine and task 
performance.    
 
Finally, it is worth noting that although the blinding procedure worked very well at 
Time 1, it was less effective at Time 2 with 69% of participants correctly guessing 
which lozenge they had received.  This is common problem with repeated measures 
designs and is not surprising, given that a direct comparison of the two lozenges is 
only possible at Time 2.  Although participants were not routinely asked how they 
could tell, informally they often commented that they could detect a strong taste or 
‘burning sensation’ in the throat.  Since between-subjects analyses of Time 1 data 
only revealed the same pattern of results as the full analysis, we can conclude that 
subjective awareness at Time 2 cannot account for all the observed effects of nicotine. 
 
The present findings have potentially important clinical implications.  For instance, 
one tentative conclusion is that, although nicotine delivered in the form of a lozenge 
can alleviate abstinence-induced impairments of reward motivation/salience 
attribution, it does not diminish the craving elicited by exposure to cigarette-related 
cues.  It is important to establish whether these deficits predict relapse, and whether 
there are individual differences in the magnitude of abstinence-induced impairments 
(e.g. reflected in personality traits or genotype) since this would enable relevant 
interventions to be targeted accordingly.  We are exploring both of these issues in this 
group of smokers as they attempt to quit. 
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Table 1 
 
ASSESSMENT 
 
ORDER OF TESTS 
 
Baseline Informed consent 
Demographic information 
Expired carbon monoxide  
Tridimensional Personality Questionnaire 
Fagerström Test of Nicotine Dependence 
Sensation Seeking Questionnaire 
Hospital Anxiety and Depression Scale (HADS) 
Eysenck Personality Questionnaire 
Smoking Motivation Questionnaire 
IVE 
Positive Emotionality Quesionnaire 
Salivary Cotinine 
 
2 to 7 days later 
 
Assessment 1  
Following overnight (12 hours) 
abstinence  
Group 1: Nicotine lozenge 
Group 2: Placebo lozenge 
Expired carbon monoxide (must be ≤ 10ppm) 
Administration of lozenge 
30 minute wait 
Spatial Working Memory Task 
Saccadic Eye Movement Task 
Verbal Fluency 
Antisaccadic Eye Movement Task 
Administration of ‘top-up’ lozenge 
CARROT or IMERS task (counterbalanced) 
Alphabet Arithmetic 
HADS 
Snaith Hamilton Pleasure Scale (SHAPS) 
Stroop  
IMERS or CARROT (counterbalanced) 
Continuous Performance Task 
Cue Reactivity 
 
One week later 
 
Assessment 2 
Following overnight (12 hours) 
abstinence 
Group 1: Placebo lozenge 
Group 2: Nicotine lozenge 
 
 
Expired carbon monoxide (must be ≤ 10ppm) 
Administration of lozenge 
30 minute wait 
Spatial Working Memory Task 
Saccadic Eye Movement Task 
Verbal Fluency 
Antisaccadic Eye Movement Task 
Administration of ‘top-up’ lozenge 
CARROT or IMERS task (counterbalanced) 
Alphabet Arithmetic 
HADS 
Snaith Hamilton Pleasure Scale (SHAPS) 
Stroop  
IMERS or CARROT (counterbalanced) 
Continuous Performance Task 
Cue Reactivity 
Procedures/assessment measures in bold represent those relevant to the present study.  
 
 
Table 2 
 
  
Lozenge Order: 
Nicotine/Placebo 
N=76 
 
 
Lozenge Order: 
Placebo/Nicotine 
N=69 
Age 
   Mean (SD) 
   Range 
 
32.43 (13.12) 
19-65 
 
31.08 (11.14) 
19-63 
 
Sex ratio (M:F) 
 
30:46 
 
33:36 
Years in further education 
   Mean (SD) 
   Range 
 
4.20 (3.51) 
0-22 
 
3.43 (2.97) 
0-13 
No. of cigarettes per day 
   Mean (SD) 
   Range 
 
18.09 (5.06) 
10-35 
 
18.14 (6.68) 
10-40 
Years of regular smoking 
   Mean (SD) 
   Range  
 
15.96 (12.76) 
1-52 
 
15.08 (11.73) 
2-48 
No. of previous quit attempts 
   Mean (SD) 
   Range 
 
2.84 (3.65) 
0-20 
 
2.61 (2.74) 
0-10 
Baseline CO 
   Mean (SD) 
   Range 
 
19.24 (9.69) 
5-48 
 
17.50 (8.36) 
4-44 
Baseline cotinine 
   Mean (SD) 
   Range 
 
253.41 (128.67) 
44.60-512.60 
 
278.25 (172.03) 
43.60-940.30 
FTND 
   Mean (SD) 
   Range 
 
4.95 (1.76) 
2-9 
 
4.81 (1.94) 
1-9 
SMQ dependence 
   Mean (SD) 
   Range 
 
13.49 (4.83) 
3-24 
 
14.98 (4.59) 
5-27 
Craving (placebo lozenge) 
   Mean (SD) 
   Range 
 
3.96 (1.74) 
1-7 
 
4.03 (1.77) 
1-7 
Craving (nicotine lozenge) 
   Mean (SD) 
   Range 
 
3.50 (1.65) 
1-7 
 
3.06 (1.64) 
1-7 
MPS (placebo lozenge) 
   Mean (SD) 
   Range 
 
6.96 (4.59) 
0-18 
 
6.87 (3.83) 
1-18 
MPS (nicotine lozenge) 
   Mean (SD) 
   Range 
 
6.50 (4.29) 
0-18 
 
5.54 (4.32) 
0-21 
FTND = Fagerstrom Test of Nicotine Dependence; SMQ=Smoking Motivation 
Questionnaire; MPS = Mood and Physical Symptoms 
 
 
 
 
Table 3 
 
  
Nicotine 
 
 
Placebo 
Craving 
   Neutral cue: mean (SD) 
   Cigarette cue: mean (SD) 
 
 
3.15 (1.76) 
3.93 (1.81) 
 
3.83 (1.71) 
4.61 (1.79) 
MPS 
Neutral cue: mean (SD) 
Cigarette cue: mean (SD) 
 
 
4.88 (3.77) 
4.85 (3.82) 
 
5.80 (4.15) 
5.76 (4.04) 
 
 
 
 
Table 4 
 
 
 
 
Nicotine 
 
 
Placebo 
 
AM trials 
AM paired control trials 
AM – control trials 
 
0.519 (0.110) 
0.452 (0.093) 
0.067 (0.078) 
 
0.544 (0.130) 
0.448 (0.116) 
0.097 (0.127) 
  
SR trials 
SR paired control trials 
SR – control trials  
0.481 (0.124) 
0.447 (0.095) 
0.034 (0.088) 
0.513 (0.149) 
0.464 (0.108) 
0.049 (0.137) 
 
 
AM – SR difference 
 
0.037 (0.112) 
 
 
0.031 (0.131) 
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 Legend for Tables and Figures 
Table 1: Schematic overview of design and order of assessments 
Table 2: Demographic and smoking-related information, and craving and withdrawal 
symptoms for the two groups tested in different orders. 
Table 3: Mean (SD) reaction times for AM and SR trials and their paired standard 
control trials under nicotine and placebo lozenge conditions.  
Table 4: Mean (SD) self-reported craving and MPS scores following exposure to neutral 
and cigarette cues under nicotine and placebo lozenge conditions.  
Figure 1: IMERS experimental framework.  130 experimental trials comprising 112 
control trials, 6 AM trials and 6 SR trials were presented in random order.  AM 
and SR symbols were counterbalanced across participants and testing sessions.  
H and L represent the targets for choice reaction time responses.   
Figure 2: Card sorting rate (cards per second) on the CARROT non-rewarded and 
rewarded trials under conditions of nicotine and placebo lozenge for all subjects. 
Error bars are +/- 1SE on the non-reward minus reward interaction. 
Figure 3:  Colour-naming errors for the four different word types on the modified 
Stroop task in nicotine and placebo lozenge conditions.  Error bars are +/- 1SE 
 
